



J. B. Chemicals announces Q3 results.

HIGHLIGHTS

- NET SALES UP 4% TO RS.13510.01 LAKHS.
- PBIDT UP 11% AT RS.2822.58 LAKHS
- PAT UP 2% TO RS.1950.90 LAKHS.
- EPS FOR THE FIRST NINE MONTHS UP 3% AT RS.7.14 (Rs.6.90)

BSE Scrip Code : 506943

NSE Symbol : JBCHEPHARM.

MUMBAI, JANUARY 22nd, 2007: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL), has announced un-audited financial results for the third quarter ended December 31, 2006. JBCPL has achieved Net Sales of Rs.13510.01 lakhs for third quarter ended December 31, 2006, as compared with Rs.13018.99 lakhs for the same period last year, registering a growth of 4%, The Profit Before Tax is Rs.2293.15 lakhs (Rs.2189.63 lakhs), reflecting an increase of 5%, while Profit After Tax stood at Rs.1950.90 lakhs (Rs.1911.40 lakhs) reflecting an increase of 2%.

Profit before Interest, Depreciation and Tax moved up to Rs. 2822.58 lakhs (Rs.2541.25 lakhs), featuring a growth of 11%. Interest outgo was Rs. 329.29 lakhs (Rs.126.62 lakhs). The Depreciation Charge is Rs.200.14 lakhs (Rs.225.00 lakhs) The Provision for Taxation is Rs. 252.25 lakhs (Rs.232.89 lakhs). Deferred Tax is Rs.75.00 lakhs (Rs.30.00 lakhs). The Fringe Benefit Tax is Rs.15.00 lakhs (Rs.20.00 lakhs). Earnings Per Share for the third quarter ended December 31, 2006 is Rs.2.32 (Rs.2.38) on an enhanced Share Capital of Rs.1685.99 lakhs. The Sales during the quarter were affected due to delay in commencement of New Large Volume Parenterals (LVP) Plant at Panoli, Gujarat.

PERFORMANCE OF NINE MONTHS

The Company has achieved Net Sales of Rs.38450.02 lakhs for the nine months ended December 31, 2006, as compared with Rs.35187.99 lakhs for the corresponding period of last year, registering an increase of 9%.

Profit before Interest, Depreciation and Tax (PBIDT) moved-up to Rs.8630.53 lakhs (Rs.7702.32 lakhs), reflecting a growth of 12%. The Interest outgo was Rs.787.42 lakhs (Rs.346.78 lakhs). The Depreciation charge increased to Rs.825.14 lakhs (Rs.825.00 lakhs). The Profit before Tax is Rs.7017.97 lakhs (Rs.6530.54 lakhs), again posting a growth of 7%. The deferred tax liability was Rs.176.22 lakhs (Rs.65.00 lakhs). The provision for taxation stood at Rs.771.98 lakhs (Rs.855.50

lakhs).The Company has achieved a Net Profit of Rs.6009.77 lakhs for the nine months period ended December 31, 2006 (Rs.5547.01 lakhs) registering an increase of 8%.

Earnings Per Share for the nine months period ended on December 31, 2006 is Rs.7.14 as compared with Rs.6.90 of the corresponding period of last year, on an enhanced Share Capital of Rs.1685.99 lakhs, reflecting an increase of 3%.

STRATEGIC INVESTMENT IN BIOTECH LABORATORIES (PTY) LTD., SOUTH AFRICA

JBCPL has signed a definitive agreement to acquire significant minority stake in Biotech Laboratories (Pty) Ltd. (biotech) of South Africa for USD 5.1 Mn, with an option to increase its holding in future. JBCPL plans to make this strategic investment through a SPV.

Biotech is a strong Black Economic Empowerment (BEE) Company and enjoys this status for the tender. This strategic investment will strengthen JBCPL's position in South Africa in terms of participation in government and sector related tenders. Moreover, it will help JBCPL to tap lucrative high growth South African and other African markets through launch of its ethical and OTC range of products including Doktor Mom.

The South Africa is the largest pharmaceutical market in Africa, valued closed to USD 3 Billion with high potential for growth.

INVESTMENT IN GUJARAT TO SET UP A PHARMA SEZ

JBCPL plans to develop and construct pharmaceutical sector specific Special Economic Zone (SEZ) at Panoli, Gujarat. JBCPL will invest about Rs.115 crore on setting-up of a SEZ infrastructure and will complete the construction work during 2009.

The SEZ will house 10 -15 Industrial Units, both Indian and International entrepreneurs from pharma sector besides JBCPL's own unit for manufacturing various dosage forms for its growing export markets. The industrial units, with a total investment of over Rs.800 crore will generate direct employment for about 6000 people and indirect employment for over 15000 people.

The benefits offered by the Government to the proposed SEZ will give a further boost to JBCPL's exports significantly. By taking this initiative as a Developer and Entrepreneur, JBCPL will continue to enjoy the tax holiday on profits. Moreover, this will also help India and in particular the state of Gujarat to create world class infrastructure facilities and expand JBCPL's share in the global Pharma market.

ABOUT J. B. CHEMICALS & PHARMACEUTICALS LTD.:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to more than 30 countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries and has successfully increased its presence in USA, Europe and Australia through Joint Ventures and Strategic Alliances. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.uniquepharma.com / www.jbcpl.com

For more details, please contact:

Beejal Desai
Vice President & Company Secretary
Head Investor Relations
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2499 1311

Kais Rahimtulla
Madison Public Relations
91 22 5654 8341/42/43
9820131613

Forward Looking Statement:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J. B. Chemicals & Pharmaceuticals Ltd. that involves risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.